Related Experiment Video
Updated: Mar 11, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm
Suchita Pakkala1, Suresh S Ramalingam1
1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Clifton Rd, Atlanta, GA 30322, USA.
Abstract:
Activating mutations in the epidermal growth factor receptor (EGFR) are present in approximately 15% of US patients with lung adenocarcinoma. EGFR tyrosine kinase inhibitors are associated with high response rate and progression-free survival for patients with non-small cell lung cancer with this genotype. Gefitinib, erlotinib, and afatinib are the EGFR tyrosine kinase inhibitors that are presently in clinical use. Understanding resistance mechanisms has led to the identification of a secondary mutational target, T790M, in more than half of patients, for which osimertinib has been approved. This article reviews the current treatments, resistance mechanisms, and strategies to overcome resistance.
Insights
Activating mutations in the epidermal growth factor receptor (EGFR) drive lung cancer. Current treatments target these mutations, but resistance develops, necessitating new strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activating mutations in the epidermal growth factor receptor (EGFR) are found in about 15% of US lung adenocarcinoma cases.
- EGFR tyrosine kinase inhibitors (TKIs) demonstrate efficacy in non-small cell lung cancer (NSCLC) patients with these mutations.
- Gefitinib, erlotinib, and afatinib are established EGFR TKIs.
Purpose of the Study:
- To review current treatments for EGFR-mutated lung cancer.
- To explore mechanisms of resistance to EGFR TKIs.
- To discuss strategies for overcoming treatment resistance.
Main Methods:
- Literature review of current treatments for EGFR-mutated lung cancer.
- Analysis of identified resistance mechanisms.
- Synthesis of strategies to overcome resistance.
Main Results:
- Resistance to EGFR TKIs is common, often due to secondary mutations like T790M.
- Osimertinib is approved for T790M-positive NSCLC.
- Understanding resistance is key to developing next-generation therapies.
Conclusions:
- EGFR-mutated NSCLC treatment requires ongoing adaptation due to resistance.
- Targeting resistance mechanisms, such as T790M, improves patient outcomes.
- Further research into novel therapeutic strategies is crucial.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...